PuSH - Publikationsserver des Helmholtz Zentrums München

42 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
1.
Böckmann, D. et al.: Cost-effectiveness of pulmonary rehabilitation in patients with bronchial asthma: An analysis of the EPRA randomized controlled trial. Value Health 24, 1254-1262 (2021)
2.
Laxy, M. et al.: Utility decrements associated with diabetes and related complications: Estimates from a population-based study in Germany. Value Health 24, 274-280 (2021)
3.
Shao, H.* ; Laxy, M. ; Gregg, E.W.* ; Albright, A.* & Zhang, P.*: Cost-effectiveness of the new 2018 American college of physicians glycemic control guidance statements among US adults with type 2 diabetes. Value Health 24, 227-235 (2021)
4.
Maqhuzu, P.N. et al.: Predictors of health-related quality of life decline in intersitial lung disease using the K-bild questionnaire. Value Health 23, S360-S360 (2020)
5.
Kirsch, F. et al.: Influence of COPD severity and its comorbidities on direct and indirect costs: Results from the LQ-DMP study. Value Health 22, S876-S876 (2019)
6.
Maqhuzu, P.N. ; Kreuter, M.* & Schwarzkopf, L.: Cost of healthcare resource utilization in interstitial lung diseases in Germany in 2017. Value Health 22, S845-S845 (2019)
7.
Szentes, B.L. et al.: The suitablility of the EQ-5D-5L in asthma patients. Value Health 22, S882-S882 (2019)
8.
Arnold, M. & Quante, A.S.: Personalized mammography screening and screening adherence-A simulation and economic evaluation. Value Health 21, 799-808 (2018)
9.
Szentes, B.L. ; Kirsch, F. ; Schramm, A.* ; Schwarzkopf, L. & Leidl, R.: Association between severe, moderate and mild exacerbations with generic health-related quality of life in COPD patients. Value Health 21, S419-S419 (2018)
10.
Walter, J. & Schwarzkopf, L.: First insights into comparing expenditures for targeted therapy and survival in NSCLC. Value Health 21, S35-S35 (2018)
11.
Arnold, M.* & Quante, A.S.: Risk-stratified breast cancer screening and non-adherence in Germany. Value Health 20, A442-A442 (2017)
12.
Hoogendoorn, M.* et al.: External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): Report of the third COPD modeling meeting. Value Health 20, 397-403 (2017)
13.
Kirsch, F.* ; Becker, C. ; Maier, W. & Schramm, A.*: Effects of adherence to pharmacological secondary prevention after myocardial infarction on healthcare expenditures. Value Health 20, A609-A609 (2017)
14.
Laxy, M. ; Wilson, E.C.F.* ; Boothby, C.E.* & Griffin, S.J.*: Incremental costs and cost-effectiveness of intensive treatment in individuals with type 2 diabetes detected by screening in the ADDITION-UK trial: An update with empirical trial-based cost data. Value Health 20, 1288-1298 (2017)
15.
Leidl, R. & Reitmeir, P.: An experience-based value set for the EQ-5D-5L in Germany. Value Health 20, 1150-1156 (2017)
16.
Seidl, H. et al.: The 3-year cost-effectiveness of a nurse-based case management versus usual care for elderly patients with myocardial infarction: Results from the KORINNA follow-up study. Value Health 20, 441-450 (2017)
17.
Szentes, B.L. et al.: Quality of life assessment in ILD - a comparison of  EQ-5D with the disease-specific K-bild. Value Health 20, A649-A649 (2017)
18.
Walter, J. ; Tufman, A.* ; Holle, R. & Schwarzkopf, L.: Comparison of costs and care of lung cancer patient at the end-of-life in Germany depending on the tome of survival after diagnosis. Value Health 20, A511-A511 (2017)
19.
Arnold, M.* & Quante, A.S.: Personalized mammography screening and screening adherence - a simulation of cost-effectiveness. Value Health 19, A738-A738 (2016)
20.
Danner, M.* et al.: Economic modeling of risk-adapted screen-and-treat strategies in women at high-risk for breast or ovarian cancer. Value Health 19, A737-A738 (2016)